The Clinical Outcome Changing in Mild Symptoms COVID-19 Patients Without Risk Factor who Received Andrographis Paniculata Crude Extract in Hospitals in UdonThani Province, 2021.

Abstract

This pilot study aimed to measure the change of symptoms in COVID-19 patients with mild symptoms who received Andrographis paniculata crude extract capsules in hospitals in Udonthani province as   adjunctive treatment. Sample was COVID-19 patients with mild symptoms without risk factor who had treated in hospital in Udonthani province from April 2021 to August 2021. They received Andrographis paniculata crude extract capsule 180 mg daily for 5 consecutive days, assessed by VAS day 1^st, 3^rd and 5^th. Descriptive statistical analyses such as frequency, percentage, mean, standard deviation, median and IQR. Friedman test used to compare clinical before and after treatment with level of statistical significance was 0.05.

Result; 344 patients were included in the study, 308 patients had complete study. Male and    female proportions was approximately the same, mean age was 20.31 years old (SD=9.80). They       revealed better in symptoms 258 patients (83.77%), symptoms did not change in 50 patients (16.23%). Mean difference VAS scores between before and after treatment showed improvement of the symptoms of severe cough, frequent cough, sore throat, fever, headache, myalgia, dyspnea, running nose , loss of taste, loss of smell and diarrhea. Almost patients had better symptoms since day 3 and had no any symptom since day 6. Although 17 patients turned to pneumonia, all of them discharged within 14 days as hospital quarantine that time.

Conclusion: Patients with mild symptoms Covid-19, no risk who received Andrographis paniculata crude extract capsules had significant reduced on severity and frequency of cough, sore throat, fever, headache, myalgia, dyspnea, running nose, loss of taste, loss of smell and diarrhea.